var data={"title":"Levonorgestrel intrauterine device: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levonorgestrel intrauterine device: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/788506?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levonorgestrel-intrauterine-device-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levonorgestrel intrauterine device: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50629653\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Levonorgestrel Intrauterine Systems Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the risk of decreased breast milk production with the use of levonorgestrel intrauterine devices (Mirena, Jaydess, and Kyleena) because of reports in women using Mirena and concluded there is limited evidence to suggest a link between levonorgestrel intrauterine devices and the risk of decreased breast milk production. Health Canada is considering updating the product information to mention that cases of decreased breast milk production in women using levonorgestrel intrauterine devices have been reported.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/birth-control-hormone-systems-intrauterine-assessing-potential-risk-less-breast-milk-production.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941935\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kyleena;</li>\n      <li>Liletta (52 MG);</li>\n      <li>Mirena (52 MG);</li>\n      <li>Skyla</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941936\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Jaydess;</li>\n      <li>Kyleena;</li>\n      <li>Mirena</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941940\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Contraceptive;</li>\n      <li>\n        Progestin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941980\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contraception:</b> Females: Intrauterine device (IUD): To be inserted into uterine cavity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kyleena: Initially releases levonorgestrel ~17.5 mcg/day, then rate subsequently decreases; the average release rate over 5 years is levonorgestrel ~9 mcg/day. Do not leave device in place for &gt;5 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Liletta: Initially releases levonorgestrel 19.5 mcg/day, then rate subsequently decreases; the average release rate over 4 years is levonorgestrel ~15.4 mcg/day. Do not leave in place for &gt;4 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mirena: Initially releases levonorgestrel 20 mcg/day, then rate subsequently decreases to half of that after 5 years. Do not leave device in place for &gt;5 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Skyla, Jaydess [Canadian product]: Initially releases levonorgestrel ~14 mcg/day after 24 days, then rate subsequently decreases; mean release rate over 3 years is levonorgestrel ~6 mcg/day. Do not leave device in place for &gt;3 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initiation of therapy:</i> The device may be inserted at any time in the menstrual cycle once it is determined that the woman is not pregnant; immediately postpartum; or immediately after first or second trimester spontaneous or induced abortion. Back-up contraception is not needed if insertion is within 7 days of onset of menstruation. If insertion occurs &gt;7 days after menstrual bleeding started, an additional form of contraception must be used for 7 days unless the woman abstains from sexual intercourse. Additional contraception is not needed if IUD is placed at the time of surgical abortion. Do not administer immediately following a septic abortion (Curtis 2016a).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer recommendations: </i>Following pregnancy or a second trimester abortion or miscarriage, insertion of the device should not take place for at least 6 weeks or until involution of the uterus is complete.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuation of contraception:</i> When it is time to replace, device may be removed and replaced with a new device immediately, and at any time during menstrual cycle as long as the woman is not pregnant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional contraceptive dosing considerations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching from a different contraceptive to levonorgestrel IUD: </i>The device may be inserted immediately if it is determined that the woman is not pregnant. Unless the woman abstains from sexual intercourse, a backup method of contraception is needed if it has been &gt;7 days since menstrual bleeding has begun. When an additional method of contraception is needed, consider continuing the woman's previous method for 7 days after insertion (Curtis 2016a).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Switching from a copper IUD: If sexual intercourse occurred after the start of the current cycle, and it has been &gt;5 days since bleeding began, consider administering an emergency contraceptive (Curtis 2016a).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Switching to Liletta or Mirena from an injectable progestin contraceptive: May be inserted at any time. If inserted &gt;13 weeks after the last injection, a barrier method of contraception should be used for 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Switching to Liletta or Mirena from a contraceptive implant or another intrauterine system: May insert on the same day the implant or device is removed, any time during the menstrual cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Switching to Liletta or Mirena from a hormonal contraceptive (oral, transdermal, vaginal): May be inserted anytime, including hormone free interval of the previous method. If inserted during active use of the previous method, continue previous method for 7 days after insertion or until the end of the current treatment cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching from levonorgestrel IUD to a different contraceptive:</i> If the patient wishes to change to a different method of birth control, may remove the device during the first 7 days of menstrual cycle and begin the new therapy. If the device is not removed during the first 7 days of menstruation (or if the patient has irregular menstrual cycles or amenorrhea) and wants to start a different method of birth control, start the new method at least 7 days prior to device removal, otherwise, a back-up barrier contraceptive should be used for 7 days after the device is removed unless the woman abstains from vaginal intercourse.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial hyperplasia, treatment (off-label use):</b> Intrauterine device (Mirena): 20 mcg/day for hyperplasia without atypia or atypical endometrial hyperplasia/endometrial intraepithelial neoplasia. Mirena contains levonorgestrel 52 mg in a reservoir which releases ~20 mcg/day over 5 years and should be replaced after 5 years; however, the optimal duration of treatment is not known (ACOG 631 2015; Armstrong 2012; Orbo 2014; Trimble 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heavy menstrual bleeding:</b> Females: Intrauterine device (Mirena): Refer to dosing for contraception</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941979\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contraception:</b> Females: Refer to adult dosing. Not for use prior to menarche.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heavy menstrual bleeding:</b> Females: Refer to adult dosing. Not for use prior to menarche.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941981\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Not indicated for use in postmenopausal women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941982\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941983\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use of the intrauterine device is contraindicated with active hepatic disease or hepatic tumor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941996\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intrauterine Device, Intrauterine: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kyleena: 19.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Liletta (52 MG): 18.6 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mirena (52 MG): 20 mcg/24 hr</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Skyla: 13.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941938\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51237794\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kyleena 19.5 mg intrauterine device initially releases approximately 17.5 mcg/day of levonorgestrel, then decreases to approximately 15.3 mcg/day after 60 days, 9.8 mcg/day after 1 year and to 7.4 mcg/day after 5 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liletta 52 mg intrauterine device initially releases 19.5 mcg/day of levonorgestrel, then decreases to approximately 17 mcg/day at 1 year, 14.8 mcg/day at 2 years, and 12.9 mcg/day at 3 years, and 11.3 mcg/day at 4 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirena 52 mg intrauterine device initially releases approximately 20 mcg/day of levonorgestrel, then decreases progressively to half that value after 5 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Skyla 13.5 mg intrauterine device initially releases approximately 14 mcg/day of levonorgestrel, then decreases to 10 mcg/day after 60 days, 6 mcg/day after 1 year, then further declines to 5 mcg/day after 3 years.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941999\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrauterine Device, Intrauterine:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Jaydess: 13.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kyleena: 19.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941984\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intrauterine device: Consider administering analgesics or cervical anesthetic prior to insertion. Insert into the uterine cavity to the recommended depth with the provided insertion device; should not be forced into the uterus. If necessary, dilate the cervical canal and consider using a paracervical block. Transvaginal ultrasound may be used to check proper placement. Remove if not positioned properly and insert a new IUD; do not reinsert removed IUD. Exclude uterine perforation if exceptional pain or bleeding occurs after insertion. Ensure device is intact after removal. Refer to manufacturer's labeling for additional administration instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132667\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. Double gloving and a protective gown are recommended for administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941944\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contraception:</b> Prevention of pregnancy (up to 3 years [Skyla], 4 years [Liletta], or 5 years [Kyleena, Mirena]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heavy menstrual bleeding (</b>\n      <b>Mirena only</b>\n      <b>)</b>: Treatment of heavy menstrual bleeding in women who also choose to use an IUD for contraception.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51011165\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Endometrial hyperplasia (treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941951\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&le;16%), migraine (&le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (6% to 15%), seborrhea (1% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypermenorrhea (5% to 59%; generally bleeding lessens after the first 90 days), amenorrhea (&le;38%, increases with duration of treatment), intermenstrual bleeding (23%), ovarian cyst (3% to 22%; includes symptomatic and asymptomatic cysts)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (&le;23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Abnormal uterine bleeding (52%), irregular menses (25% to 43%; menses becomes more regular after the first 90 days), vulvovaginitis (11% to 24%), pelvic pain (&le;23%), vaginal infection (18%), vaginal discharge (4% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Vulvovaginal infection (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (8%), depression (4% to 6%), mood changes (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&lt;5%), skin rash (&lt;5%), urticaria (&lt;5%), alopecia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Oligomenorrhea (8% to 10%; periods may become more infrequent after the first 90 days), weight gain (6%), decreased libido (&lt;5%), hirsutism (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;9%), vomiting (&le;9%), abdominal distress (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Mastalgia (3% to 10%), dysmenorrhea (&le;10%), uterine spasm (&le;10%), dyspareunia (9%), breast tenderness (&le;8%), endometritis (&le;2%), genitourinary tract infection (upper, 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (5% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Device expulsion (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Central nervous system: Bipolar mood disorder (exacerbation), exacerbation of depression, suicidal tendencies</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, arterial thromboembolism, breakage of IUD, cerebrovascular accident, cervical perforation, deep vein thrombosis, hypersensitivity reaction, increased blood pressure, jaundice, malignant neoplasm of breast, myocardial infarction, pelvic inflammatory disease, sepsis (including Group A streptococcal sepsis), uterine hemorrhage, uterine perforation, venous thromboembolism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941948\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Hypersensitivity to levonorgestrel or any component of the formulation; pregnancy or suspected pregnancy; postcoital contraception; congenital or acquired uterine anomaly, including fibroids that distort the uterine cavity and would be incompatible with correct IUD placement; acute pelvic inflammatory disease or endometritis or history of pelvic inflammatory disease (unless there has been a subsequent intrauterine pregnancy); infected abortion within past 3 months; known or suspected uterine or cervical neoplasia; untreated acute cervicitis or vaginitis (including bacterial vaginosis, known chlamydial or gonococcal cervical infection) or other lower genital tract infections until infection is controlled; conditions which increase susceptibility to pelvic infections; unremoved IUD; uterine bleeding of unknown etiology; acute hepatic disease or hepatic tumors (benign or malignant); current or history of known or suspected breast cancer or other hormone-sensitive cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Bacterial endocarditis; recent trophoblastic disease while human chorionic gonadotropin (hCG) hormone levels are elevated; cervical dysplasia; known immunodeficiency or hematologic malignancy (Mirena)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941949\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding irregularities: Menstrual bleeding patterns may be altered, especially during the first 3 to 6 months with use of the intrauterine device (IUD) and result in spotting, irregular bleeding, heavy bleeding, oligomenorrhea and amenorrhea; the possibility of pregnancy should be considered if menstruation does not occur within 6 weeks of the previous menstrual period. If significant bleeding irregularities continue with prolonged use, appropriate diagnostic measures should be taken to rule out endometrial pathology (polyps or cancer). An increase in menstrual bleeding may indicate a partial or complete expulsion of the IUD (see dosage form specific issues). Unexplained vaginal bleeding should be evaluated prior to insertion (Curtis 2016b); use is contraindicated with unexplained uterine bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia/syncope: Bradycardia or syncope may occur during insertion or removal of the IUD; use with caution in patients predisposed to these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer: Breast cancer is a hormonal sensitive tumor. Use is contraindicated in women with (or history of) breast cancer. Reports of breast cancer have been reported with levonorgestrel-releasing IUDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ectopic pregnancy: Use caution in patients with previous ectopic pregnancy. Women with history of ectopic pregnancy were excluded from clinical trials; women with previous ectopic pregnancy, tubal surgery or pelvic infection may be at increased risk for ectopic pregnancy. The possibility of ectopic pregnancy should be considered in patients with lower abdominal pain, especially in association with missed periods or vaginal bleeding in women with prior amenorrhea. Ectopic pregnancy may result in loss of fertility.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: IUD may need to be removed (temporarily or permanently) if ophthalmic problems or discomfort occur, including issues related to contact lenses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian cysts: May occur during IUD use; most are asymptomatic and disappear spontaneously within 2 to 3 months. Evaluate if persistent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pelvic inflammatory disease: An increased incidence of group A streptococcal sepsis, pelvic inflammatory disease (PID) or endometritis (may be asymptomatic), and actinomycosis have been reported with use. Using aseptic technique during insertion is essential to minimizing the risk of serious infections. PID occurs more frequently within the first year and most often within the first month after insertion; risk is increased with multiple sexual partners. Women with a history of PID or endometritis are at increased risk. If PID is diagnosed, treat according to current guidelines and reassess in 24 to 48 hours. Remove IUD 24 to 48 hours after beginning antibiotics if there is no clinical improvement or if the woman wishes to discontinue use (Curtis 2016a). Women with symptomatic actinomycosis should have the device removed and be treated with the appropriate antibiotics. Remove IUD in cases of recurrent endometritis or PID, or if an acute pelvic infection is severe or does not respond to treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure: Insertion or removal may be associated with seizure, especially in patients predisposed to seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cervical or endometrial cancer: Women diagnosed with cervical or endometrial cancer prior to IUD insertion should not use an IUD for pregnancy prevention (may have in increased risk of bleeding or infection when the device is inserted). Women diagnosed after insertion of an IUD may continue; however, the IUD will most likely need to be removed during treatment (Curtis 2016b). Use is contraindicated in women with progestin sensitive cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with depression; may be more susceptible to recurrence of depressive episodes; consider removal of IUD for serious recurrence. Depression is not a contraindication to use of the IUD (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gestational trophoblastic disease: Women with gestational trophoblastic disease are at increased risk of adverse events if pregnancy occurs; use of the levonorgestrel IUD may be appropriate for prevention of pregnancy in some situations with close medical supervision. However, women with persistently elevated beta-hCG concentrations or malignant disease with evidence or suspicion of intrauterine disease should not initiate therapy with a levonorgestrel IUD due to risks of infection, hemorrhage, or perforation. Consider benefits of effective contraception versus risks of continuation/removal in women who have a levonorgestrel IUD already in place (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sepsis: The levonorgestrel IUD should not be inserted in women with postpartum sepsis or immediately following a septic abortion (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sexually transmitted disease: Use of the levonorgestrel IUD should not be initiated in women with purulent cervicitis, chlamydial or gonococcal infection. The IUD does not need to be removed if diagnosis occurs with the IUD in place, as long as there is treatment with appropriate antibiotics, and consideration is given to personal risk factors and patient preference (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: The levonorgestrel IUD may be inserted in women with nonpelvic tuberculosis; do not initiate treatment in cases of pelvic infection and consider removal when pelvic infection occurs with the IUD in place (2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Liletta: Body weight was not found to influence contraceptive efficacy in overweight, obese, or morbidly obese women.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not for use prior to menarche.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postmenopausal women: Not indicated for use in postmenopausal women.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Smokers: The risk of cardiovascular side effects increases in women using estrogen containing combined hormonal contraceptives and who smoke cigarettes, especially those who are &gt;35 years. This risk relative to progestin-only contraceptives has not been established. Women who take contraceptives should be advised not to smoke. Smoking is not a contraindication to use of the IUD (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Consent form: Some products provide a consent form; a copy of the form and lot number should be kept with the woman's medical record.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Expulsion: Partial or complete expulsion may occur, may be associated with symptoms of bleeding or pain, or may be asymptomatic and go unnoticed. An increase in menstrual bleeding may indicate a partial or complete expulsion of the IUD. The risk of expulsion may be increased when the uterus is not completely involuted. If expulsion occurs, remove device; may replace device within 7 days of a menstrual period once pregnancy is ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Magnetic resonance imaging (MRI): Only under specific conditions may Skyla or Jaydess [Canadian product] be scanned safely by MRI. Image quality may also be impaired if area of interest is relatively close to the device. Kyleena and Liletta are MRI safe.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Perforation: Total or partial perforation may occur, most often during insertion, and may include penetration/embedment in the uterus or cervix; risk of perforation is increased in lactating women and when the uterus is fixed retroverted or not completely involuted during the postpartum period. Perforation may reduce contraceptive efficacy and result in pregnancy. If perforation occurs, locate and remove IUD; delayed detection or removal in cases of perforation may result in migration of IUD outside of uterine cavity, adhesions, peritonitis, intestinal perforations, intestinal obstruction, abscesses, and erosion of adjacent viscera.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: IUD: Insertion should be done by a trained health care provider. Insertion and removal may be associated with pain and/or bleeding; consider analgesics prior to insertion. Removal of the device may be necessary for the following reasons: pelvic infection or disease, endometritis, symptomatic genital actinomycosis, uterine or cervical cancer, uterine or cervical perforation, partial expulsion, and pregnancy. Use with caution if any of the following conditions exist and consider removal if any of them arise during use: Coagulopathy or are receiving anticoagulants; marked increase of blood pressure; severe arterial disease, such as stroke or MI; exceptionally severe headache; and migraine, focal migraine with asymmetrical visual loss, or other symptoms indicating transient cerebral ischemia. In addition, consider removal if jaundice occurs during use. Not effective for emergency contraception.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV infection protection: Intrauterine devices do not protect against HIV infection or other sexually transmitted diseases (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941958\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941955\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104541&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acitretin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May decrease the serum concentration of Progestins (Contraceptive). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May decrease the serum concentration of Progestins (Contraceptive). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Progestins (Contraceptive). However, atazanavir may lead to decreased ethinyl estradiol concentrations and decreased effectiveness of oral contraceptive products. Management: Consider an alternative or additional method of contraception, particularly with combined estrogen/progestin products. Depot medroxyprogesterone acetate may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bexarotene (Systemic): May decrease the serum concentration of Progestins (Contraceptive). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Progestins (Contraceptive). Management: Administer oral progestin-containing contraceptives at least 1 to 4 hours prior to or 4 to 6 hours after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Progestins (Contraceptive). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Progestins (Contraceptive). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May decrease the serum concentration of Progestins (Contraceptive). Management: Females of childbearing potential should use an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Progestins may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carfilzomib: May enhance the thrombogenic effect of Progestins (Contraceptive). Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloBAZam: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Progestins (Contraceptive). Management: Consider an alternative, non-hormone-based contraceptive in patients receiving cobicistat-containing products. Drospirenone is specifically contraindicated with atazanavir and cobicistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of Progestins (Contraceptive). Management: Females of reproductive potential should use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Consider using an alternative or additional means of contraception.  Injected depot medroxyprogesterone acetate may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eslicarbazepine: May decrease the serum concentration of Progestins (Contraceptive). Management: Alternative, non-hormonal means of birth control should be considered for women of child-bearing potential.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May decrease the serum concentration of Progestins (Contraceptive). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: Progestins (Contraceptive) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Progestins (Contraceptive) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Progestins (Contraceptive).  Management: Consider using an alternative or additional means of contraception.  Injected depot medroxyprogesterone acetate may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May decrease the serum concentration of Progestins (Contraceptive). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixazomib: May decrease the serum concentration of Progestins (Contraceptive). More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of contraceptive progestins. Management: Patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lesinurad: May decrease the serum concentration of Progestins (Contraceptive). Management: Use of an additional, nonhormonal contraceptive is recommended in patients being treated with lesinurad who desire effective contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lixisenatide: May decrease the serum concentration of Progestins (Contraceptive). Management: Administer oral contraceptives 1 hour before or at least 11 hours after administration of lixisenatide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May decrease the serum concentration of Progestins (Contraceptive). Lopinavir may increase the serum concentration of Progestins (Contraceptive). Management: Consider using an alternative or additional means of contraception.  Injected depot medroxyprogesterone acetate and etonogestrel implants may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of Progestins (Contraceptive). Management: Do not rely on hormone-based contraceptives with concurrent use of lumacaftor/ivacaftor; an alternative, non-hormonal, method of contraception should be used if this combination is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May decrease the serum concentration of Progestins (Contraceptive). Metreleptin may increase the serum concentration of Progestins (Contraceptive).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Progestins (Contraceptive). MiFEPRIStone may increase the serum concentration of Progestins (Contraceptive). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: May decrease the serum concentration of Progestins (Contraceptive). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May decrease the serum concentration of Progestins (Contraceptive). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: May decrease the serum concentration of Progestins (Contraceptive). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May decrease the serum concentration of Progestins (Contraceptive). Management: Patients should use an alternative, nonhormonal-based form of contraception both during the concurrent use of perampanel and for 1 month after discontinuing perampanel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May diminish the therapeutic effect of Progestins (Contraceptive). Management: The combination of hormonal contraceptives with pitolisant should be avoided, and an alternate means of contraception should be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Progestins may enhance the thrombogenic effect of Pomalidomide.  Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: May diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.<b> Exceptions: </b>Adapalene; Bexarotene (Topical); Tretinoin (Topical).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selegiline: Progestins (Contraceptive) may increase the serum concentration of Selegiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May decrease the serum concentration of Progestins (Contraceptive). Management: Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May decrease the serum concentration of Progestins (Contraceptive). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Progestins (Contraceptive) may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May decrease the serum concentration of Progestins (Contraceptive). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tranexamic Acid: Progestins (Contraceptive) may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Progestins may diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins.  Management: Ulipristal for uterine fibroids (Canadian indication): avoid progestins within 12 days of stopping ulipristal; as emergency contraceptive (U.S. indication): avoid progestins within 5 days of stopping ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Progestins (Contraceptive) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Progestins (Contraceptive). Progestins (Contraceptive) may increase the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941945\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use during pregnancy or a suspected pregnancy is contraindicated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnancy should be ruled out prior to insertion. Women who become pregnant with an IUD in place risk septic abortion; septicemia, septic shock, and death may occur. Removal of the device is recommended; however, removal or manipulation of IUD or probing of the uterus may result in pregnancy loss. In addition, if pregnancy occurs with an IUD in place, the likelihood of ectopic pregnancy is increased; miscarriage, sepsis, premature labor, and premature delivery may occur if pregnancy is continued. Following pregnancy or a second trimester abortion or miscarriage, the manufacturer recommends that insertion of the device should not take place for at least 6 weeks or until involution of the uterus is complete. The device may be inserted immediately following a first trimester abortion. Following removal of the device, ~71% to 88% of women who wished to conceive became pregnant within 12 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941947\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levonorgestrel is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Following maternal use of the oral tablets or IUD, levonorgestrel can be detected in the serum of breastfeeding infants (Shikary 1987). In general, no adverse effects on the growth or development if the infant have been observed. Isolated cases of decreased milk production have been reported. Risk of perforation with IUD is increased in lactating women. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Following pregnancy, the manufacturer recommends that insertion of the device should not take place until 6 weeks postpartum or until involution of the uterus is complete. Guidelines note the levonorgestrel IUD may be inserted immediately postpartum in breastfeeding women, including women who had a cesarean delivery. The risk of infection is not increased; the risks of expulsion may be increased and this risk should be considered along with the need for effective contraception and patient access to placement at a later time (Curtis 2016b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941988\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior to insertion: Assessment of pregnancy status; bimanual examination and cervical inspection; weight (optional; BMI at baseline may be helpful to monitor changes during therapy); STD screen (unless already screened according to CDC STD Treatment guidelines) (Curtis 2016a). Complete medical and social history which may determine conditions influencing an IUD use for contraception.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Following insertion: Transvaginal ultrasound may be used to check placement. Changes in health status (including medications) should be assessed at routine follow-up visits (Curtis 2016a). Re-examine following insertion (4 to 6 weeks Kyleena, Liletta, Mirena, Skyla; 4 to 12 weeks Jaydess [Canadian product]) and then yearly or more frequently if necessary. Threads should be visible; if length of thread has changed device may have become displaced, broken, perforated the uterus, or expelled. Monitor for significant changes in menstrual bleeding during prolonged use, Pap smear, blood pressure, serum glucose in patients with diabetes. Patients presenting with lower abdominal pain should be evaluated for ovarian cysts and ectopic pregnancy. Signs of infection. Monitor for signs/symptoms of thromboembolism in women who require surgery with prolonged immobilization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endometrial hyperplasia, treatment (off-label use): Endometrial sampling every 3 to 6 months, although most appropriate frequency has not been determined (ACOG 631 2015; Trimble 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941965\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kyleena: Plasma concentrations range from 175 &plusmn; 74 pg/mL (7 days following insertion) to 90 &plusmn; 35 pg/mL (after 5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liletta: Plasma concentrations range from a peak of 252 pg/mL (7 days following insertion) to 135 pg/mL (after 4 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirena: Plasma concentrations range from 150 to 200 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Skyla, Jaydess [Canadian product]: Plasma concentrations range from a peak of 192 pg/mL (2 days following insertion) to 59 to 61 pg/mL (after 3 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941963\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pregnancy may be prevented through several mechanisms: Thickening of cervical mucus, which inhibits sperm passage through the uterus and sperm survival; inhibition of ovulation, from a negative feedback mechanism on the hypothalamus, leading to reduced secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH); altering the endometrium, which may affect implantation. Levonorgestrel is not effective once the implantation process has begun. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44941966\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Kyleena, Mirena: Up to 5 years; Liletta: up to 4 years; Skyla, Jaydess [Canadian product]: Up to 3 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~1.8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Highly bound to albumin (~50%) and sex hormone-binding globulin (~47%) (Fotherby 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4; forms inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~45%); feces (~32%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44942000\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Intrauterine Device</b> (Kyleena Intrauterine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">19.5 mg (1): $1,090.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Intrauterine Device</b> (Liletta (52 MG) Intrauterine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18.6 mcg/day (1): $821.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Intrauterine Device</b> (Mirena (52 MG) Intrauterine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg/24 hrs (1): $1,090.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Intrauterine Device</b> (Skyla Intrauterine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13.5 mg (1): $908.24</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45524741\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fleree (LV);</li>\n      <li>Janess (IL);</li>\n      <li>Jaydess (AU, BE, BG, CH, CZ, DK, FR, GB, IE, KR, MT, NZ, RO, SG, SI);</li>\n      <li>Levosert (BG, GB, HR, LU, MT);</li>\n      <li>Lovosert (LV);</li>\n      <li>Mirena (AE, AT, AU, BB, BE, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, LK, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, PY, QA, RO, RU, SE, SG, SI, TH, TR, UA, VN, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25797236\"></a>Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. <i>Am J Obstet Gynecol.</i> 2015t;213(4):469-478. doi: 10.1016/j.ajog.2015.03.037.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/25797236/pubmed\" target=\"_blank\" id=\"25797236\">25797236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25932867\"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice, Society of Gynecologic Oncology. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. <i>Obstet Gynecol.</i> 2015;125(5):1272-1278. doi: 10.1097/01.AOG.0000465189.50026.20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/25932867/pubmed\" target=\"_blank\" id=\"25932867\">25932867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22863972\"></a>Armstrong AJ, Hurd WW, Elguero S, et al. Diagnosis and management of endometrial hyperplasia. <i>J Minim Invasive Gynecol.</i> 2012;19(5):562-571. doi: 10.1016/j.jmig.2012.05.009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/22863972/pubmed\" target=\"_blank\" id=\"22863972\">22863972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27467319\"></a>Curtis KM, Jatlaoui TC, Tepper NK, et al. US selected practice recommendations for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016a;65(4):1&#8208;66. doi: 10.15585/mmwr.rr6504a1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/27467319/pubmed\" target=\"_blank\" id=\"27467319\">27467319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27467196\"></a>Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016b;65(3):1&#8208;103. doi: 10.15585/mmwr.rr6503a1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/27467196/pubmed\" target=\"_blank\" id=\"27467196\">27467196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23724525\"></a>Dolapcioglu K, Boz A, Baloglu A. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study. <i>Clin Exp Obstet Gynecol.</i> 2013;40(1):122-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/23724525/pubmed\" target=\"_blank\" id=\"23724525\">23724525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fotherby K. Levonorgestrel. Clinical pharmacokinetics. <i>Clin Pharmacokinet</i>. 1995;28(3):203-215.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/7758251/pubmed\" target=\"_blank\" id=\"7758251\">7758251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frank ML and DiMaria C, &ldquo;Levonorgestrel Subdermal Implants,&rdquo; <i>Drug Saf</i>, 1997, 17(6):360-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/9429835/pubmed\" target=\"_blank\" id=\"9429835\">9429835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta J, Kai J, Middleton L, et al, &quot;Levonorgestrel Intrauterine System versus Medical Therapy for Menorrhagia,&quot; <i>N Engl J Med</i>, 2013, 368(2):128-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/23301731/pubmed\" target=\"_blank\" id=\"23301731\">23301731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaydess (levonorgestrel) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyleena (levonorgestrel-releasing intrauterine system) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyleena (levonorgestrel) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liletta (levonorgestrel) [prescribing information]. Irvine, CA: Allergan USA Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McNicholas C, Maddipati R, Zhao Q, et al. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. <i>Obstet Gynecol</i>. 2015;125(3):599-604. doi:10.1097/AOG.0000000000000690.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/25730221/pubmed\" target=\"_blank\" id=\"25730221\">25730221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirena (levonorgestrel) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirena (levonorgestrel) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24286192\"></a>Orbo A, Vereide A, Arnes M, et al. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. <i>BJOG.</i> 2014;121(4):477-486. doi: 10.1111/1471-0528.12499.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/24286192/pubmed\" target=\"_blank\" id=\"24286192\">24286192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plan B (levonorgestrel). Saint-Laurent, Quebec, Canada: Paladin Labs Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Preshaw PM. Oral contraceptives and the periodontium. <i>Peridontol 2000.</i> 2013;61(1):125-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/23240947/pubmed\" target=\"_blank\" id=\"23240947\">23240947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shikary ZK, Betrabet SS, Patel ZM, et al, &quot;ICMR Task Force Study on Hormonal Contraception. Transfer of Levonorgestrel (LNG) Administered Through Different Drug Delivery Systems from the Maternal Circulation into the Newborn Infant's Circulation via Breast Milk,&quot; <i>Contraception</i>, 1987, 35(5):477-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/3113823/pubmed\" target=\"_blank\" id=\"3113823\">3113823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitruk-Ware R and Nath A, &quot;Metabolic Effects of Contraceptive Steroids,&quot; <i>Rev Endocr Metab Disord</i>, 2011, 12(2):63-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/21538049/pubmed\" target=\"_blank\" id=\"21538049\">21538049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skyla (levonorgestrel) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23090535\"></a>Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. <i>Obstet Gynecol.</i> 2012;120(5):1160-1175. doi: http://10.1097/AOG.0b013e31826bb121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levonorgestrel-intrauterine-device-drug-information/abstract-text/23090535/pubmed\" target=\"_blank\" id=\"23090535\">23090535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104541 Version 59.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50629653\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F44941935\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F44941936\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F44941940\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F44941980\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F44941979\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F44941981\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F44941982\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F44941983\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F44941996\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F44941938\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F51237794\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F44941999\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F44941984\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132667\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F44941944\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F51011165\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F44941951\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F44941948\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F44941949\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F44941958\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F44941955\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F44941945\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F44941947\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F44941988\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F44941965\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F44941963\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F44941966\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F44942000\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45524741\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/104541|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levonorgestrel-intrauterine-device-patient-drug-information\" class=\"drug drug_patient\">Levonorgestrel intrauterine device: Patient drug information</a></li></ul></div></div>","javascript":null}